PDS Biotech initiates VERSATILE-003 Phase 3 trial for Versamune HPV in head and neck cancer

PDS Biotechnology Corp

Phase 3 trial VERSATILE-003 now open to patient enrollment for HPV16-positive head and neck cancer.
Trial to enroll ~350 patients at 2:1 ratio; primary endpoint is overall survival.
First-ever Phase 3 trial in HPV16-positive head and neck cancer.
Versamune HPV already has FDA Fast Track designation based on Phase 2 data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.